Tumor Localization by Tumor Infiltrating Lymphocytes Labeled with Indium-111 in Patients With Metastatic Renal Cell Carcinoma, Melanoma, and Colorectal Cancer

1997 ◽  
Vol 12 (2) ◽  
pp. 65-71 ◽  
Author(s):  
Robert O. Dillman ◽  
S. Robert Hurwitz ◽  
Patric M. Schiltz ◽  
Neil M. Barth ◽  
Linda D. Beutel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Infiltrating Lymphocytes ◽  
Tumor Localization ◽  
Indium 111 ◽  
Infiltrating Lymphocytes

scholarly journals Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

Oncotarget ◽  
2015 ◽  
Vol 6 (28) ◽  
pp. 24990-25002 ◽  
Author(s):  
Marina K. Baine ◽  
Gabriela Turcu ◽  
Christopher R. Zito ◽  
Adebowale J. Adeniran ◽  
Robert L. Camp ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma

1999 ◽  
Vol 17 (8) ◽  
pp. 2521-2521 ◽  
Author(s):  
Robert A. Figlin ◽  
John A. Thompson ◽  
Ronald M. Bukowski ◽  
Nicholas J. Vogelzang ◽  
Andrew C. Novick ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Control Group ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

PURPOSE: To prospectively evaluate in a multicenter randomized trial the antitumor activity of CD8+ tumor-infiltrating lymphocytes (TILs) in combination with low-dose recombinant interleukin-2 (rIL-2), compared with rIL-2 alone, after radical nephrectomy in metastatic renal cell carcinoma patients. PATIENTS AND METHODS: Between December 1994 and March 1997, 178 patients with resectable primary tumors were enrolled at 29 centers in the United States and Europe. Patients underwent total nephrectomy, recovered, and were randomized to receive either CD8+ TILs (5 × 107 to 3 × 1010 cells intravenously, day 1) plus rIL-2 (one to four cycles: 5 × 106 IU/m2 by continuous infusion daily for 4 days per week for 4 weeks) (TIL/rIL-2 group) or placebo cell infusion plus rIL-2 (identical regimen) (rIL-2 control group). Primary tumor specimens were cultured at a central cell-processing center in serum-free medium containing rIL-2 to generate TILs. RESULTS: Of 178 enrolled patients, 160 were randomized (TIL/rIL-2 group, n = 81; rIL-2 control group, n = 79). Twenty randomized patients received no treatment after nephrectomy because of surgical complications (four patients), operative mortality (two patients), or ineligibility for rIL-2 therapy (14 patients). Among 72 patients eligible for TIL/rIL-2 therapy, 33 (41%) received no TIL therapy because of an insufficient number of viable cells. Intent-to-treat analysis demonstrated objective response rates of 9.9% v 11.4% and 1-year survival rates of 55% v 47% in the TIL/rIL-2 and rIL-2 control groups, respectively. The study was terminated early for lack of efficacy as determined by the Data Safety Monitoring Board. CONCLUSION: Treatment with CD8+ TILs did not improve response rate or survival in patients treated with low-dose rIL-2 after nephrectomy.

Sign in / Sign up

Export Citation Format

Share Document